CLSTN2 and cancer: These results show that: After the expression of Lnc-CLSTN2-1:1 was knocked down in osteosarcoma cells by RNAi technology, the in vivo and in vitro experimental results suggested that the expression level of antioxidant system selenate (GPx, TrxR) was decreased, while the expression level of ROS was increased, destroying REDOX balance and the damage of ROS to cancer cells.